Scibase Holding
0,44 SEK -4,35%39 investorer følger denne virksomhed
SciBase Holding is a medical technology company. The Group specializes in the management of cancer diagnostics, mainly focused on the treatment and detection of various melanomas. The company has developed an electric handheld probe that analyzes the measurement signal to detect specific changes in the body's skin tissue. The head office is located in Stockholm.
P/E (24e)
-1,53
EV/EBIT (adj.) (24e)
-1,54
P/B (24e)
3,9
Udbytteafkast, % (24e)
-
Kursmål
0.32 SEK
Anbefaling
Reducer
Opdateret
3.6.2024
First North Stockholm
SCIB
Daglig lav / høj pris
0,44 / 0,488
SEK
Markedsværdi
96,6 mio. SEK
Aktieomsætning
167,02 t SEK
Volumen
364 t
Business risk
Valuation risk
Current
Previous
Seneste analyser
Extensive report
Inderes' extensive report is an investor's handbook on customer companies covered by our research.
The latest extensive report was released
Read the reportAnalyst
![Antti Luiro Antti Luiro](https://www.inderes.se/cdn-cgi/image/format=auto,width=128,height=128,quality=90,fit=cover/https://core.inderes.fi/sites/default/files/2023-08/Antti_Luiro.jpg)
Antti Luiro
Head of Nordic ER Development, Analyst
Seneste videoer
Finanskalender
Delårsrapport
21.08.2024
Delårsrapport
12.11.2024
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Gell Group | 11,0 % | 11,0 % |
Avanza Pension | 9,7 % | 9,7 % |
Premium
This content is for our Premium customers only.
Resultatopgørelse
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Omsætning | 9,5 | 11,7 | 17,9 | 23,2 | 31,2 | 47,6 | 77,1 | 122,5 |
vækst-% | 2,6 % | 23,2 % | 52,6 % | 29,9 % | 34,4 % | 52,5 % | 61,9 % | 58,9 % |
EBITDA | -32,2 | -38,7 | -42,8 | -50,6 | -53,1 | -44,2 | -25,9 | 3,7 |
EBIT (adj.) | -34,8 | -41,6 | -46,4 | -53,9 | -56,4 | -47,2 | -29,1 | 0,3 |
EBIT | -34,8 | -41,6 | -46,4 | -53,9 | -56,4 | -47,2 | -29,1 | 0,3 |
Overskud før skat | -35,0 | -41,8 | -43,2 | -53,9 | -53,3 | -47,7 | -29,6 | -0,2 |
Netto indkomst | -35,0 | -41,8 | -43,2 | -53,9 | -53,3 | -47,7 | -29,6 | -0,2 |
EPS (adj.) | -1,12 | -0,67 | -0,63 | -0,50 | -0,29 | -0,22 | -0,13 | -0,00 |
vækst-% | ||||||||
Udbytte | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
Udbytte ratio |
Lønsomhed og afkast på kapital
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
EBITDA-% | -337,7 % | -329,6 % | -239,1 % | -217,5 % | -170,0 % | -92,7 % | -33,5 % | 3,0 % |
EBIT-% (adj.) | -365,2 % | -354,8 % | -259,5 % | -232,0 % | -180,7 % | -99,1 % | -37,7 % | 0,2 % |
EBIT-% | -365,2 % | -354,8 % | -259,5 % | -232,0 % | -180,7 % | -99,1 % | -37,7 % | 0,2 % |
ROE | -88,7 % | -71,0 % | -89,9 % | -158,0 % | -157,3 % | -5.258,7 % | 78,4 % | 0,5 % |
ROI | -88,2 % | -70,7 % | -96,7 % | -158,0 % | -166,5 % | -171,3 % | -75,7 % | 0,4 % |
Værdiansættelse
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Aktiekurs (SEK) | 4,48 | 5,36 | 3,71 | 0,83 | 0,44 | 0,44 | 0,44 | 0,44 |
Aktier | 54,8 | 68,5 | 68,5 | 119,8 | 219,5 | 219,5 | 219,5 | 219,5 |
Markedsværdi | 245,6 | 366,9 | 253,9 | 99,9 | 96,6 | 96,6 | 96,6 | 96,6 |
Enterprise value | 204,2 | 301,3 | 235,1 | 65,8 | 86,9 | 140,3 | 180,1 | 196,4 |
EV/S | 21,4 | 25,7 | 13,1 | 2,8 | 2,8 | 2,9 | 2,3 | 1,6 |
EV/EBITDA | - | - | - | - | - | - | - | 52,7 |
EV/EBIT (adj.) | - | - | - | - | - | - | - | 784,6 |
EV/EBIT | - | - | - | - | - | - | - | 784,6 |
P/E (adj.) | - | - | - | - | - | - | - | - |
P/E | - | - | - | - | - | - | - | - |
P/B | 5,2 | 5,2 | 10,1 | 2,3 | 3,9 | - | - | - |
P/S | 25,8 | 31,3 | 14,2 | 4,3 | 3,1 | 2,0 | 1,3 | 0,8 |
Udbytteprocent | ||||||||
Equity ratio | 79,1 % | 82,8 % | 50,6 % | 66,9 % | 47,3 % | -33,8 % | -52,1 % | -35,3 % |
Gearing ratio | -88,4 % | -92,7 % | -74,6 % | -79,2 % | -39,0 % | -190,7 % | -159,1 % | -189,3 % |
Kvartalsdata
Q2/23 | Q3/23 | Q4/23 | 2023 | Q1/24 | Q2/24e | Q3/24e | Q4/24e | 2024e | |
---|---|---|---|---|---|---|---|---|---|
Omsætning | 5,1 | 7,2 | 5,8 | 23,2 | 6,1 | 7,3 | 9,1 | 8,7 | 31,2 |
EBITDA | -12,8 | -12,0 | -15,7 | -50,6 | -13,4 | -14,0 | -12,7 | -12,9 | -53,1 |
EBIT | -13,8 | -12,7 | -16,6 | -53,9 | -14,3 | -14,9 | -13,5 | -13,8 | -56,4 |
Overskud før skat | -13,8 | -12,7 | -16,6 | -53,9 | -10,9 | -15,0 | -13,6 | -13,9 | -53,3 |
Netto indkomst | -13,8 | -12,7 | -16,6 | -53,9 | -10,9 | -15,0 | -13,6 | -13,9 | -53,3 |
ViserAlle indholdstyper
SciBase partner with a large health care group in Los Angeles, Unified Health, and receives a first order
SciBase welcomes new chairman and thanks the former
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Annual general meeting has been held in SciBase Holding AB (publ)
SciBase strengthens the US organization with experienced leader in dermatology
![SciBase: Building faster growth takes time](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/546a3302-f056-45d5-9957-11ead5ab01d5.png)
SciBase: Building faster growth takes time
Redeye: Scibase - Stepping up the pace
SciBase: Interim report
SciBase: Today is the first day of trading in the new shares and warrants of series TO 2 issued in connection with the completed capital raising
SciBase already received first order from Austria
SciBase receives first order in Austria
SciBase Announces the launch of eBarrier Score, the First AI-Driven Skin Barrier Assessment tool for research and Cosmetic Testing
![SciBase Q1’24 preview: Still modest growth as US ramp-up is gathering speed](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/d2087f10-cc7c-4f60-9099-06a80ba4a818.png)